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  Quinone methides (QMs) are electrophilic intermediates that can be generated in 
vivo to alkylate DNA and function as anti-cancer drugs. Previously, DNA-QM 
conjugates have shown the ability to selectively deliver a QM to specific sequences of 
DNA. Peptide nucleic acids (PNAs) conjugates of QM are now being developed since 
PNA binds DNA with higher affinity than natural DNA. Synthesis of PNA oligomers 
and conjugation of the PNA to QM precursor are reported here. 
Synthesis of peptides was used to study the optimum conditions for preparation of 
the ultimate peptide-PNA conjugate. Both peptides and peptide-PNA have been 
synthesized after optimizing solid-phase techniques. Conditions for coupling a 
quinone methide precursor (QMP) and peptide-PNA conjugates were also evaluated. 
8-Amino-3,6-dioxaoctanoic acid that links PNA and QMP is essential for coupling. 
MOPS buffer containing the peptide-PNA and an acetonitrile/dimethylformamide 
  
mixture containing QMP were combined for coupling. Finally, reactive QM 
derivative of peptide-PNA-QM was studied. 
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Chapter 1: Introduction 
 
1.1 Importance of DNA alkylation 
Double helix DNA consists of two twisted polymers with phosphoribose 
backbones (Figure 1.1).1 Four bases, adenine, thymine, guanine and cytosine are 
linked to their backbones (Scheme 1.1). 
 
Scheme 1.1 Structures of DNA bases adenine, thymine, guanine and cytosine 
DNA is constantly modified by intracellular and extracellular chemicals. The 
modification of DNA may result in covalent changes and cause severe diseases like 
cancer. Many methods being developed to DNA level which may cure cancer rely on 
DNA modification. DNA alkylation is one type of DNA modification. 
Some natural products can alkylate DNA. These compounds are active in blocking 
the growth of tumor cells, but most of these compounds also show lack selectivity 




alkylation agents to cells is an effective method to reduce the side-effect of these 
compounds. 
 
Figure 1.1 DNA double helix1 
 
1.2 DNA alkylation agents 
The nitrogen mustards are natural DNA alkylating agents and have been 
intensively studied as a class of anti-cancer drugs.2 Bis(2-chloroethyl)methylamine 
(1.5) and chlorambucil (1.6) are two typical molecules of nitrogen mustards (Scheme 
1.2).  
 




Bis(2-chloroethyl)methylamine shows high activity by inducing DNA interstrand 
cross-links (Scheme 1.3). The reaction is promoted by a near neighbor effect. The 
three-member ring intermediate is formed by losing a chloride and then attacked by 
nucleophiles from DNA. Mono-DNA adduct (1.7) is generated first. Bis-DNA adduct 
(1.8) can then be generated by a second loss of chloride.  
 
Scheme 1.3 DNA alkylation by bis(2-chloroethyl)methylamine 
Compounds 1.9 in which two guanine residues are bridged via their respecitve N7 
atoms by one mechlorethamine was isolated from mechlorethamine-treated yeast 
RNA.3, 4 The structure of 1.9 shows that the cellular target of DNA is alkylated 
primarily at the N7 position of guanine compared to lesser reaction at the N3 position 
of adenine (Scheme 1.4). 
 




Although DNA interstrand and DNA-protein crosslinks can be produced from 
bis(2-chloroethyl)methylamine, the DNA interstrand crosslink formed between the 
two complementary strands of DNA is believed to be the major cytotoxic lesion.5 
Epoxide-containing agents are another kind of DNA alkylating agents. Four 
stereoisomers 7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene BPDE 
(1.10 - 1.13) generated in vivo shows the ability of epoxide-containing agents to 
alkylate DNA (Scheme 1.5). 6, 7 
 
 




These compounds are highly active due to the benzylic epoxide. Several adduct are formed 
while N2 of deoxyguanosine adduct is predominant.7 (+)-Anti-BPDE-DNA adduct is 
found to inhibit RNA8 and DNA9 polymerases. 
The generation of epoxide via cytochrome P-450 in vivo is a typical theme in 
biological systems. The oxidation of aflatoxin (1.15) is a good example. The epoxide 
intermediate (1.16) formed via cytochrome P-450 oxidation will alkylate DNA. The 
DNA residues most susceptible to alkylation by these agents include dG N7, dA N6, 
and dC N3.10 
 
Scheme 1.6 DNA alkylation by aflatoxin 
Mitomycin C (1.18) is from a family of aziridine-containing natural products. It is 
used in cancer treatment by alkylating DNA (Scheme 1.7).11 These effects are 
dependent on reductive bioactivation of mitomycin C. Generated by the reduction of 
mitomycin C, 2,7-diaminomitosene (1.19) is the major intermediate. The intermediate 





Scheme 1.7 Generation of DNA adduct from mitomycin C via QM 
The intermediate 1.19 plays an important role in the alkylation process and it is 
also a kind of compounds called quinone methides (QMs). 
 
1.3 Qunione Methides (QM) 
QMs are a class of compounds that contain a methylene in place one of the oxygen 
atoms in quinone.12, 13 There are two major types of QMs: o-QM (1.21) and p-QM 
(1.22) (Scheme 1.8).  
 




QM is a strong electrophile and can be attacked by nucleophile from the methylene 
group, regenerating the aromatic ring. Due to its high reactivity, QM is usually 
generated in situ and used immediately. QMs are involved not only in the traditional 
organic synthesis, but also in a variety of biochemical reactions.14-17 
QMs can be generated from thermal methods,18 UV light,19, 20 desilyation of silyl 
ethers by fluoride,21  oxidation by Ag2O and PbO2,22, 23 and biological methods.24  
Anthracycline is an important class of anti-tumor antibiotics. Daunomycin (1.23) 
and adriamycin (1.24) are two of these anti-tumor structures (Scheme 1.9).25 The 
mechanism of their high biological activity is proposed via QM mediates. In order to 
verify the idea, Ag2O oxidation was used to convert the daunomycin analog (1.25) to 
generate QM intermediate (1.26). 1.26 is attacked by nucleophiles such as EtOH, 
H2NPh and NaCN.25 Then it is reasonable to think that QM is the essential 
intermediate in alkylating DNA. The biological activity of daunomycin and 
adriamycin may go through the QM intermediate. 
 




The adriamycin analog (1.25) was synthesized to evaluate the function of QM 
intermediate during the reaction.  
Desilyation of silyl ethers by fluoride is also extensively used to study the 
generation and react of QMs with DNA.26-29 Compounds 1.28 and 1.29 represent this 
type of quinone methide precursor (QMP) which are used to help understand the 
property of QM (Scheme 1.10).  
 
Scheme 1.10 Models of silyl ether protected QMP 
The hydroxyl group is protected by silyl ether and a good leaving group is linked to 
the benzylic positon. The generation of QM is triggered by adding fluoride. This 
method generates QMs which can be used in situ quickly and effectively. 
Since there are A, T, G and C nucleobases in DNA, lots of sites may function as 
target to alkylation. The Rokita group has studied the kinetic and thermodynamic 
property of the adducts from unsubstituted QMs and individual nucleobases as well as 
DNA sequences.26 The QM intermediates often shows a selectivity for some 
nucleophiles of DNA.30 The reactions between QM and weak nucleophiles such as 
N1, N2 of dG and N3 of dC are irreversible, while the QM adducts generated with 
strong nucleophiles such as N1 of dA, N3 of dC and N7 of dG show reversibility. The 




The substituents on QMs affect the formation and stability of their nucleophilic 
adducts tremendously.31 When an electron-withdrawing group is present, its dC N3-
QM adduct was stablized. However, a related adduct with an electron-donating 
methyl group on the QM is very labile and regenerates its QM rapidly. By changing 
different electronics of the QM functional groups, the reversibility of QM-
nucleobases adducts show them be the desired balance of liability and stability. 
The lack of selectivity toward DNA sequences is a major problem for all the DNA 
alkylating agents. In order to increase the efficiency of QMs and reduce the side-
effect in normal cells, selective delivery of QMP is an essential topic.  
Rokita group also studied the selective delivery of QMP.27 Selective alkylation of a 
chosen sequence of DNA can be accomplished by linking QMP to the complementary 
DNA.  
 
Scheme 1.11 Selective delivery of QMP by DNA sequence27 
After QMP was coupled with a DNA sequence (OD1), the acetate derivative (1.31) 




attacked by DNA and formed DNA-QM self-adduct (1.32). Due to the reversibility of 
the self-adduct, target DNA sequence (OD2) was alkylated (1.33) when the 
complementary DNA was mixed with 1.32 (Scheme 1.11).27 
However, the use of DNA as selective delivery agents has its limitation. The 
degradation of oligonucleotides caused by cellular nucleases and lack the membrane 
permeability makes other sequence directing agents important. Peptide Nucleic Acids 
(PNAs) are one of the choices gaining lots of interest recently. 
 
1.4 PNAs Function as sequence specific delivery agents 
First designed by scientists from Denmark,32 PNA is synthesized and used in 
binding with both DNA and RNA in a site-selective manner by Watson-Crick base-
pairing. PNA is a chemical similar to DNA and RNA but differs in its “backbone” 
(Scheme 1.12). The backbone of PNAs is composed of repeating N-(2-aminoethyl)-
glycine units. Through the methylene carbonyl bonds, the purine (A, G) and 
pyrimidine (C, T) bases are linked with the backbone. Several important properties of 
PNA make them a powerful tool in sensitive DNA diagnostics and gene therapeutics.  
The original purpose of synthesizing PNA was to recognize double-stranded DNA. 






Scheme 1.12 Backbones of DNA and PNA 
PNA is also capable of inhibiting translation in vivo and may suitable as a DNA 
probe.34, 35 PNAs are shown to resist to nucleases and proteases in vivo.33 If OD1 in 
Scheme 1.11 is replaced by PNA sequence, the PNA oligomers can selectively 
deliver QMP to cellular enviroment. 
The structure of PNA monomers also makes them easily employed in synthesis of 
PNA oligomers. The PNA monomers have both amine terminus and carboxylic acid 
terminus. Because of the similarity of PNA components and amino acids, PNA can be 
easily synthesized by standard solid phase peptide synthesis (SPPS)36, 37 which is 
widely used in peptide synthesis.  
First developed by Merrifield R.B. in early 1960s,36 SPPS allows the synthesis of 




classical synthesis since it avoids the complicate separation procedures that are 
associated with the liquid phase peptide synthesis.  
After PNA oligomers are synthesized through SPPS, QMP can be coupled with 
PNA chain. Once the selective delivery agents are determined, it is important to find a 
target in cells. 
 
1.5 Function of telomerase and why choose telomerase as a target 
Telomeres are highly repeated DNA-protein structures (5’-TTAGGG-3’ in 
vertebrates) at the ends of linear chromosomes.38 Human telomeres contain about 5-
15 kilobases of a tandem repeat sequence. They distinguish the natural termini from 
random breaks and protect the loss of important genes in chromosomes. These 
structures also help to stabilize DNA during replication.39 Telomeres keep shortening 
after each cell cycle.40 Once the length of telomeres decreases to minimum threshold, 
the protective telomere caps become destabilized and result in replicative senescence 
or the death of cells.41  
In some human cell types such as adult germline cells and stem cells, telomeres 
are not always shortening with the proliferation of cells due to the existence of 
telomerase.42 Telomerase is an enzyme that adds specific DNA sequence repeats 
("TTAGGG" in all vertebrates) to the 3' end of DNA strands in the telomere 
regions.43 In most normal cells, telomerase activity is almost undetectable.44 While 
telomerase activity is found in most human tumors.45 The length of the telomeres in 
tumor cells does not continuously shorten with the successive cell divisions because 




factor in the “immortal”46 property of cells by adding the repeating sequences to the 
telomeres (Scheme 1.13).  
Thereby, telomerase is a potential target for the anti-tumor drugs. The length of 
telomere in the cells will shorten corresponding to the cells divisions if the telomerase 
can be inhibited by a drug.  
 
Scheme 1.13 Binding of the end of telomere by human telomerase47 
Several methods have been developed to deactivate telomerase.48 Oligonucleotide-
based therapeutics is just one of the potential methods to develop anti-cancer drugs by 
binding to the appropriate site inside the telomerase. There are two subunits in human 
telomerase: hTR and hTERT. The RNA hTR acts as a template for replication and the 
protein hTERT catalyzes nucleotide polymerization.37 The hTR has 451 nucleotides, 
and nucleotides 45-65 (5’-CTAACCCTAAC) provide an appropriate binding site for 
direct inhibition of telomerase activity. By using a peptide nucleic acid (PNA), 5’-
GTTAGGGTTAG-3’ is found to inhibit telomerase effectively.47  
Because of the use of QMPs and PNA oligomers, we will study the synthesis of 
PNA oligomers and peptide-PNA conjugates by SPPS. Optimal conditions for 
coupling peptide-PNA conjugates with QMP are also discussed in detail. Finally, 




examined. The synthesis of PNA oligomers and peptide-PNA-QMP self-adduct 




Chapter 2: Synthesis of peptide-PNA conjugate 
 
2.1 Introduction to Solid-Phase Peptide Synthesis (SPPS) 
Natural peptides have multiple functions as hormones, cytokins and enzymes in 
living cells. The biosynthesis and function of peptides in cells are important to 
understand the cause of various diseases. In order to study the biological property and 
activity of peptides, a large amount of different length and types of peptides were 
synthesized. Liquid phase peptide synthesis is used in making short peptides. For long 
peptides, solid phase peptide synthesis (SPPS) is favored by eliminating the difficulty 
of purifying the products in every step. One of the best properties of SPPS is the easy 
separation of byproducts during synthesis. SPPS36 has been a standard technique in 
construction of peptides effectively for almost 50 years.  
Reaction was carried out in a fritted funnel inserted into a side arm flask through a 
single hole rubber septa (Appendix). A T-valve was at the bottom of the funnel. The 
side-arm of the T-valve was connected to a Schlenk line. The reaction is taken in the 
funnel by bubbling nitrogen through the Schlenk line. When the reaction is complete, 
the remaining starting material and byproducts are washed away by the appropriate 
solvents such as methylene chloride (DCM) or N,N-dimethylformamide (DMF) 
through a filter. The intermediate linked on the insoluble resin is the only species 
remaining in the funnel for next cycle. 
The solid-phase process consists of several steps repeated in a cyclic fashion 




coupled with the free amine groups from the resin. The protected amine terminus is 
then deprotected by corresponding deprotection reagents. When the byproducts are 
washed away, the free amine group from the first amino acid is ready to react with the 
following amino acids. By repeating the coupling, deprotecting and washing 
procedures, a desired peptide chain is formed at the solid resin. Finally, removal of 
the peptide chain from the resin is achieved by swelling resin in cleavage solution. 
 




Several steps are important to improve the yields and decrease the byproducts.49 
First is the protecting group for the N-terminal of the amino acids. In order to avoid 
polymerization of the amino acid itself, the N-terminal of amino acids is protected 
before the coupling. The protecting reagents are called ‘temporary’ protecting group 
compared to ‘permanent’ protecting group which protects the possible amine groups 
at the side chain of amino acids. The temporary protecting groups are removed after 
the coupling in every cycle, while permanent protecting groups are not removed until 
the peptide is remove from the resin by cleavage solution. Use of ‘temporary’ and 
‘permanent’ groups is showed in lysine for t-Butyloxycarbonyl (t-Boc)36 SPPS 
(Scheme 2.2). 
 
Scheme 2.2 Structures of lysine and ‘temporary’ (red), ‘permanent’ (blue) groups 
protected lysine 
If lysine (2.1) is used directly in SPPS, lysine dimer or trimer may be formed. So 
Boc-Lys-OH (2.2) is introduced, the polymerization of lysine will be avoided since 
the α-amine group is protected by the Boc temporary group. The Boc group can be 
removed by trifluoroacetic acid (TFA) effectively. Another problem rises with use of 




with carboxylic acid from other amino acids. To avoid this problem, Boc-Lys(2-ClZ)-
OH (2.3) was developed. The free amine group on the side chain of lysine is 
protected with 2-chlorobenzyloxycarbonyl group. The 2-chlorobenzyloxycarbonyl 
group is called a ‘permanent’ protecting group because it is stable to the TFA 
treatment. The 2-chlorobenzyloxycarbonyl is only sensitive to cleavage solution such 
as hydrofluoric acid (HF) and trifluoromethanesulfonic acid (TFMSA). After every 
TFA deprotection cycle, Boc group that protectsα-amine is removed while 2-
chlorobenzyloxycarbonyl is still remains and protects the amine of the side chain. 
When the synthesis is finished, the cleavage solution (HF or TFMSA for Boc protocol) 
will remove the ‘permanent’ protecting group and remove the peptides from the resin. 
t-Boc and 9-flourenylmethloxycarbonyl (Fmoc)50 are the two most used 
‘temporary’ protecting groups in SPPS (Scheme 2.3).  
 





In t-Boc protocols, the ‘temporary’ protecting group is removed by TFA after each 
coupling. When the desired peptides have been synthesized on the resin, HF or 
TFMSA are used to remove the peptide from the resin. When the protecting group is 
Fmoc, 20% piperidine in DMF is used to remove Fmoc protecting group. Finally, the 
peptides are removed from the resin by TFA.  
Fmoc protocol avoids repeated use of TFA needed for the Boc method. Fmoc is 
used in most peptides synthesis due to the milder condition required. Boc protocol is 
still used in the synthesis of some basic liable peptides and long amino acid peptides. 
Coupling efficiency is an important factor in SPPS. If the average coupling 
efficiency is 90%, after 10 cycles, the final yield is only about 35% and lots of 
byproducts are produced. One way to make the reaction go to completion with high 
efficiency is to activate the carboxylic acid terminal of the amino acids first and then 
couple with the amine groups. Many kinds of activating agents have been discovered 
including N,N’-dicyclohexylcarbodiimide (DCC),51 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU), O-(7-aza-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and 2-(6-Chloro-1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) 
(Scheme 2.4). 
DCC is widely used because of its high activity and low cost. HATU, HBTU and 
HCTU are commonly used in activating amino acids since the byproduct 
dicyclohexylurea (DCU) is insoluble in DCM. HATU is the most expensive reagent 
among the three hexafluorophosphates, while it works the best. It is usually used 





Scheme 2.4 Structure of DCC, HATU, HBTU and HCTU 
SPPS is also used in synthesizing PNA oligomers35. Scheme 2.5 shows the 
benzyloxy-carbonyl (Z) protected PNA monomers which can be used in SPPS 
through the Boc protocol. Boc protocol is found to works better than Fmoc in PNA 
synthesis.52 
 
Scheme 2.5 Z-protected PNA- A,T,G and C monomers 
Because of the neutral property of the PNA backbone and its availability through 
SPPS, we design new peptide-PNA conjugates S1 and S2. Conjugate S1 mainly 




(Scheme 2.6). Compound S2 attaches an additional 8-amino-3,6-dioxaoctanoic acid 
(mini-PEG) at the 5’ terminus of arginine. 
 
Scheme 2.6 composition of compounds S1 and S2 
  Several reasons are considered to design compounds S1 and S2:  
a) The PNA and peptide sequence can be synthesized by SPPS and QM 
precursor can be linked with the Arg at the 5’ terminus of the PNA sequence 
by standard protocol.27 
b) Kemptide53 (5’-LRRASLG-3’) is readily phosphorylated by protein kinase A 
(PKA) at the Ser site. Thus the LRRASLG sequence in compound S1 and S2 
can function as a phosphorylation site in place of the standard 5’-
phosphorylation of DNA. 
c) PNA (5’-GTTAGGGTTAG-3’) complementary to the telomerase RNA 
sequence can bind with the RNA in telomerase tightly and may inhibit the 
function of telomerase effectively.47  
d) The amine group at the 5’ terminus of the peptide-PNA conjugate S1 may be 
hindered by the peptide and PNA chain. The bifunctional mini-PEG54 was 
attached at the 5’ terminus of the conjugate as a linker to elongate the free 
amine group. This amine group may react with our DNA alkylating agent 




e) The use of PNA in vivo is hampered by its poor water solubility. Hydrophilic 
mini-PEG helps the solubility of conjugate in water due to the hydrogen 
bond between water molecules and the oxygen atoms in the mini-PEG chain.  
 
2.2 Result and Discussion 
2.2.1 Conditions for the synthesis of peptides 
Conditions for t-Boc proctol in SPPS were evaluated by synthesizing the 7mer and 
8mer peptides 5’-LRRASLG-3’ (S3) and 5’-RLRRASLG-3’ (S4). The protected 
natural amino acids that were necessary for reaction, Boc-leucine (Boc-Leu-OH), 
Boc-Alanine (Boc-Ala-OH), Boc-O-benzyl-L-serine (Boc-Ser(Bzl)OH), Nα-Boc-Ng-
mesitylenesulfonyl-L-arginine (Boc-Arg(Mts)-OH), Boc-Glycine (Boc-Gly-OH) are 
illustrated in Scheme 2.7.  
 




  Several factors contribute to the successful synthesis of peptides. There are no 
specific requirements for the gas used in peptide synthesis. Several groups suggest the 
use of nitrogen gas in PNA synthesis.34, 37 Pure nitrogen gas was used to eliminate the 
effect of water from air. So nitrogen gas was used in these experiments to achieve 
best result. 
4-Methylbenzhydrylamine hydrochloride (MBHA) resin (Scheme 2.8) was used in 
reaction. 
 
Scheme 2.8 Structure of MBHA resin 
 Two types of MHBA resins were tried in SPPS. Because PNA synthesis works 
better at low substitution (0.1-0.3 mmol/g),52 we decided to use low substitution (0.1 
mmol/g) resin to synthesize the 7mer peptide S3 at first. When S3 was coupled with 
resin, following PNA oligomers could be linked with the peptide. I found that the low 
substitution resin did not work in the reaction. This may be caused by the low 
concentration of amino acids in solution or low coupling efficiency. Typically, 5 
equivalents of each amino acid in 4 mL DMF was used in the coupling steps to ensure 
the reaction complete. When 100 mg of low substitution resin was used, the amount 
of resin is approximately 10 µmol. 50 µmol of amino acid was activated in 4 ml DMF 
with HBTU. The concentration of amino acid is 12.5 µM, but typically the 
concentration of amino acid used in coupling should be 100 µM. The low 
concentration of amino acids may have caused the failure of coupling. 
The resin was then changed to a standard substitution (0.7 mmol/g). When 100 mg 




ml DMF. The coupling was monitored by Kaiser test55 and worked well. This show 
the concentration 140 µmol is suitable for the SPPS. 
The carboxylic acid group from amino acids was activated by HBTU for two 
minutes. When five equivalents of the amino acid (compared to resin), 4.5 equivalent 
HBTU and ten equivalent N,N'-Diisopropylethylamine (DIPEA) were mixed in DMF 
for two minutes, the color of solution changed to slightly yellow. The resulting 
solution was added and coupled with resin. 
Various coupling times were also tried. Normally, the time should be no more than 
one hour. In several papers, about 30 minutes were used to finish coupling.37, 56 
During my experiment, 20 minutes and 30 minutes showed no difference in coupling. 
Less than 20 minutes was not tested. 
A procedure named ‘capping’ was also performed after the first coupling. It is 
reasonable to think that after the completion of the first coupling of the amino acid to 
the resin, there are still free amine groups at the surface of the resin. Capping solution 
(5 ml, acetic anhydride/pyridine/ N-Methylpyrrolidone = 2/1/1) was added to the 
resin only after the first coupling to ensure the consumption of all free amine groups. 
Capping between the first and second coupling will decrease the occurrence of 
byproducts.49 
95% TFA (TFA/m-cresol=95/5) can deprotect t-Boc group in 5 minutes.49 In our 
experiment, the same method was used. t-Boc protected product was swelled in 95% 
TFA twice (4 minutes each time) to remove t-Boc completely. When the Kaiser test55 




every coupling and deprotecting procedure to verify the completion of reaction. This 
is considered an effective way to monitor every step of reaction. 
In literature, cleavage solution is used to remove the peptide from the resin.49 The 
cleavage solution (trifluoromethanesulfonic acid (TFMSA)/TFA/m-cresol/ thioanisole 
= 2/6/1/1 ) was cooled to -20℃ before using. The cleavage time is one hour. All the 
other reagents, solvents are procedures were handled under room temperature. At first, 
I followed the time from literature. The resin was treated by cleavage solution one 
hour. The yield was only about 10%. Then the procedure was revised. The resin was 
first treated with cleavage solution for one hour, the resulting solution was collected. 
Then the resin was treated with another part of new cleavage solution for one hour. 
The resulting solution was collected and combined with the previous solution. 
Experiment shows that resin treated by cleavage solution twice (one hour everytime), 
the yield is more than 50%. 
If the coupling could not be finished in one day, the N-terminal of final amino acid 
should be t-Boc protected and the resin be kept under vacuum. 
After the peptides were precipitated from cold diethyl ether, the peptides were 
purified by C18 reverse-phase high performance liquid chromatography (RP-HPLC). 
The eluents are 0.1% TFA in water and 0.1% TFA in acetonitrile.  
2.2.2 Synthesis of peptide-PNA conjugate 
Basic procedure of synthesizing peptide-PNA conjugates are derived from the 
peptides synthesized above. However, after the PNA monomers were used, several 
changes were applied. 





Scheme 2.9 Peptide-PNA conjugates S1, S2 
 PNA monomers and oligomers are easily to attach at the surface of glasswares.52 
Thus plastic tubes were used to hold all PNA solutions. Plastic vials were applied to 
collect the peptide-PNA conjugates solution which were purified from RP-HPLC. 
Different from most amino acids, PNA monomers are difficult to dissolve in DCM or 
N-methylpyrrolidone (NMP) which are widely used in peptide synthesis. DMF works 
as a good solvent for PNA dissolution.  
To activate the PNA monomers, HATU was added to DMF solution of PNA 
monomers. Typical procedure for activating PNA monomers is to dissolve PNA 
monomers and HATU in DMF. Then DIPEA is added to activate the carboxylic acid 
from amino acids. The only difference is PNA monomer G. Since PNA monomer G 
is difficult to dissolve in DMF, PNA monomer G was first dissolved in DMF by 
vortex for 5-10 minutes. HATU and N N-Diisopropylethylamine (DIPEA) were then 
added to the DMF solution containing PNA monomer G.  
Resin used in peptide synthesis is 0.7 mmol/g while the recommended 
concentration of resin for PNA synthesis is 0.1mmol/g to 0.3mmol/g.52 The peptide 
chain coupled to the resin (100 mg resin, the amount of peptide on it is 70 µmol, 






Scheme 2.10 Capping after the first PNA(G) monomer was coupled with peptide. 
The unreacted peptide (blue in R2) was capped with capping solution and 
 terminate the reaction 
35 µmol (0.5 equivalent) of PNA monomer in 1 ml DMF was used in the first 
PNA(G) coupling to download the substitution of resin. Since this amount of PNA 
monomer (35 µmol) is not sufficient to couple with all the free amine groups from the 
previous amino acid (70 µmol), only part of the free amine groups from peptides were 
reacted with PNA(G) (R2, red colored). The other free amino groups were remaining. 
Then capping solution (acetic anhydride/pyridine/ N-Methylpyrrolidone = 2/1/1) was 
used to terminate the amine groups. After the capping procedure, only Boc-PNA-




resin was swelled in 95% TFA, the Boc-PNA-peptide-resin can be converted to NH2-
PNA-peptide (red in R4) while the AcO-PNA-peptide (blue in R4) would not change. 
When the second activated PNA monomer was mixed with resin, only NH2-PNA-
peptide could react with the second PNA monomer while the AcO-PNA-peptide kept 
unchanged. From the second PNA monomer, regular cycles were taken to couple 
corresponding PNA monomers to the resin.  
By applying SPPS, peptides S3, S4 and peptide-PNA conjugates S1, S2 were 
successfully synthesized. 
2.2.3 Conclusion 
Through the synthesis of peptides, we found the concentration of amino acids for 
coupling should be 50 µM or higher. O-benzyl (Bzl) is suitable for protecting serine 
side chain and Ng-mesitylenesulfonyl (Mts) is good for protection of the Arginine 




2.3.1 General method: 
Beckman Avanti J-25I centrifuge was used to separate the peptides and peptide-
PNA conjugates from diethyl ether. Labconco lyophilizer was used to lyophilize 
peptides and peptide-PNA samples. RP-HPLC separation was accomplished by 
JASCO PU980. The column employed was Varian C-18 column (Microsorb-MV 300, 




with SHIMADZU-KRATOS Axima-CFR MALDI-TOF and JEOL AccuTOF-CS 
ESI-MS. 
2.3.2 Materials 
Solvents, starting materials, and reagents of the highest commercial grade were 
used without further purification. Aqueous solutions were prepared with distilled, 
deionized water with a resistivity of 18.9 MΩ. All the Boc-protected amino acids and 
4-methylbenzhydrylamine (MBHA) resin (0.7mmol/g) were purchased from 
Advanced ChemTech. The following Boc-protected amino acid derivatives were used: 
Boc-Arg(Mts)-OH and Boc-Ser(Bzl)-OH. Mini-PEG was purchased from Peptide 
International. DMF (peptide synthesis), DCM, TFA, Ac2O, DIPEA, NMP, TFMSA, 
α-cyano-4-hydroxycinnamic acid (CHCA) and sinapinic acid (SA) were purchased 
from Acros. Kaiser test kit was obtained from Aldrich. 
Kaiser Test:55 
The Kaiser Test kit includes 6% ninhydrin solution in ethanol, ~80% phenol 
solution in ethanol and potassium cyanide solution in pyridine. Three drops of 
solution from each bottles was added to a test tube which contains about 1 mg of resin, 
then the solution was heated for 5 minutes at 100℃. If the solution turns purple, free 
amine groups are present. If the color does not change, free amine groups are absent. 
Peptide Synthesis (for first 7 amino acids in the sequence) The peptides and 
peptide-PNA conjugates were synthesized following the revised t-Boc SPPS 
chemistry.34 
Reaction was carried out in a 20 ml fritted funnel inserted into a 250 ml side arm 




The side-arm of the T-valve was connected with the Schlenk line. By forcing the 
nitrogen from the T-valve and frit, solvent and resin can be fully mixed by bubbling. 
When the vacuum was attached with the side arm of the 250 ml flask, the solvent in 
the vial was forced down to the flask and separated with the resin.  
Standard substituted MBHA resin 100 mg (0.7 mmol/g, 70 µmol) was swelled in 
DMF for 3 hours at room temperature. Then the DMF was removed and the resin was 
washed by 3 ml DCM for 1 minute twice. 
2.5 ml DMF was added to the vial that contains the desired amino acids (5 eq., 350 
µmol) and HBTU (4.5 eq. 315 µmol). DIPEA (10 eq. 700 µmol) was then added to 
the resulting solution. The solution was vortexed for 2 minutes to activate the 
carboxylic terminus and then added to the fritted funnel at room temperature. The 
solvents were mixed with resin by bubbled nitrogen at room temperature for 20 
minutes and removed by vacuum. The resin was then washed by 3 ml DMF for 1 
minute twice and 3 ml DCM for 1 minute twice. Kaiser test was performed to confirm 
the efficiency of coupling. If Kaiser test shows blue, the coupling was repeated.  
The completion of the first amino acid coupled with resin was monitored by Kaiser 
test. Ac2O/NMP/Pyrdine (5 ml, v/v=1/2/2) capping solution was added to the resin to 
cap the remaining free amine groups and reaction was mixed by bubbling N2. The 
capping solution was removed after 1 hour incubation at room temperature by passing 
the liquid through filter. 3ml DMF was used to wash the resin for 1 minute twice. 
After removing DMF, 3 ml DCM was applied to wash resin for 1 minute twice. 
The Boc protecting group was removed before the second coupling by mixing with 




once and used to wash the resin for 1 minute four times after the 95% TFA was 
removed. Additional 3 ml DMF washing for 1 minute twice followed by 3 ml DCM 
washing for 1 minute twice were carried out to fully remove the TFA. The presence 
of amine group was tested by Kaiser test.  
When deprotection was finished, the second amino acid (350 µmol), HBTU (315 
µmol) and DIPEA (700 µmmol) was mixed for the second coupling. The procedure 
was repeated until all the amino acids were added consequently. The product was 
purified by RP-HPLC (Figure 2.1) and confirmed by both MALDI-TOF (Figure 2.2) 
and ESI-MS (Figure 2.3). 
 
Figure 2.1 RP-HPLC of a) blank injection; b) 7mer peptide (5’-LRRASLG-3’) at 





Figure 2.2 MALDI of 7mer peptide (5’-LRRASLG-3’), Calculated mass: 770.9, 
MALDI found: 771.3, CHCA as matrix 
 
Figure 2.3 ESI-MS of 7mer peptide (5’-LRRASLG-3’), Calculated mass: 770.9, 
[M+2H+] = 386.45, ESI-MS found: 386.24. (In this MS spectrum, the difference of 
main peak and 2nd peak is 0.5. The difference is caused by an isotope effect. Since 
this effect is an integer, a minimum of 2 charges must be present: 1.0/0.5 = 2, there 
are two charges on the peptide. If the difference is 0.33, there are three charges on the 
peptide) 




After the 7 amino acids 5’-LRRASLG-3’ peptide was coupled onto the resin, the 
reactive amines of the nascent oligomer was decreased from 0.7 mmol/g to 0.1 
mmol/g because the PNA coupling works well at low loading resin.52 (40 mg peptide-
preloaded resin was used in peptide-PNA synthesis. The amount of free amine group 
was 28 µmol (0.7 mmol × 40 mg = 28µmol). Then half amount of PNA(G) monomer 
was used in peptide-PNA synthesis (14 µmol) to download the substitution of resin. 
The unreacted free amine group was then terminated by capping solution. So 
therotically, the substitution should be 0.35 mmol/g. However, considering the yield 
of peptides was lower in the coupling reaction, we assumed the substitution was 0.1 
mmolg/g. It is a pretty rough estimation. The following PNA coupling worked well 
depends on this assumption.) 
  40 mg peptide-preloaded resin was used. The first PNA monomer (14 µmol) and 
HATU (13 µmol) was dissolved in DMF. DIPEA (30 µmol) was transferred to the 
resulting solution. The solution was fully mixed by vortex mixing. Then the activated 
PNA monomer was mixed with H2N-LRRASLG-resin. Capping 
(Ac2O/Pyridine/NMP = 2/1/1) was applied again after the first coupling finished. 
   When the first PNA coupling and capping was finished, 1.5 ml 95% TFA/m-cresol 
(v/v=95/5) was incubated for 4 minutes twice to remove the Boc group. When the 
TFA was removed by vacuum, 3 ml DCM was used to wash the resin for 1 minute 4 
times. 3 ml NMP washing for 1 minute twice and 3 ml DCM washing for 1 minute 
twice were carried out to wash resin. When the presence of free amine group was 
confirmed by the Kaiser test (the color turns to blue), following activated PNA 




1.2 ml DMF was added to the vial that contained PNA monomers (30 µmol) and 
HATU ( 27 µmol). Then DIEA (60 µmol) was added to the previous solution. The 
solution was vortexed for 1.5 minutes to activate the carboxylic terminus and was 
added to the fritted funnel. Mixed by bubbled nitrogen at room temperature for 20 
minutes, the solvents were removed by vacuum. The resin was then wash by DMF for 
1 minute ( 2 × 3 ml ) and DCM for 1 minute ( 2 × 3 ml).  
The procedure was repeated until all the PNA monomers were added consequently. 
When all the synthesis was finished, methanol was used to fully wash the resin for 1 
minute ( 1 × 3 ml ). The resin was then dried under vacuum overnight before cleavage. 
Converting Mini-PEG. Dicyclohexylamine (DCHA) salt to Mini-PEG 
244 mg (0.5 mmol) of Mini-PEG • DCHA was suspended in 10 ml of ethyl acetate 
in a 100 mL erlenmeyer flask with a magnetic stir bar. When product was dissolved, 
Ca. 5 ml ice-cold 1 N HCl was added and the pH was adjusted to pH = 2. A white 
precipitate formed. The precipitate was separated by filteration and was washed with 
2 x 20 ml ethyl acetate. All ethyl acetate layers were combined and washed with 2 x 
20 ml of brine. Organic layer was then collected and dried over MgSO4 for 30 
minutes. The drying agent was removed by filtration. The free acid of Mini-PEG at 
the bottom of flask was collected after removing the ethyl acetate in a rotary 
evaporator (Yield = 90.0%).  
Link Mini-PEG with the peptide-PNA chain 
1.0 ml DMF was used to dissolve Mini-PEG (25 mg, 94.9 µmol). HATU (85.0 




the resulting solution was added to resin to couple Mini-PEG to resin and followed 
standard SPPS procedure. 
   Cleaving the peptide from resin 
1.5 mL cleavage solution was used for 50 mg resin. The cleavage solution consists 
of 1 part thioanisole, 1 part m-cresol, 2 parts TFMSA and 6 parts neat TFA. The 
solution was cooled under -20℃ before using. It is found that freshly opened TFMSA 
has the best result34. Long stored TFMSA may turn to brown or black and shows poor 
cleavage efficiency. 
50 mg of resin and 1.5 ml cleavage solution were incubated by barely bubbled 
nitrogen in the fritted funnel for 1 h at room temperature. The black cleavage solution 
was separated with the resin by vacuum and collected. Additional 1.5 ml cleavage 
solution was add to the funnel and was bubbled another 1 h. After the additional 
cleavage solution, 2 parts of neat TFA (3 ml) was used to wash the resin. All the 
solutions were combined. TFA was removed by continuously blowing nitrogen to the 
bottle. Finally the peptide was precipitated by mixing the cleavage solution with 50 
ml cold diethyl ether. The precipitant and solution was centrifuged at 5000 rpm for 5 
min. Additional 5 ml cold ether was used to wash the solid peptide-PNA conjugate 3 
times. The solid at the bottom of the vials was redissolve in HPLC grade acetonitrile 
and transferred to plastic bottles. The crude peptide-PNA conjugates solution was 
finally dried by lyophilizer. Molecular weight was got from MALDI-TOF. For 
peptide-PNA conjugate S1 (NH2-Arg-GTTTAGGGTTAG-LRRASLG), calculated 




S2 (NH2-MiniPEG-Arg-GTTTAGGGTTAG-LRRASLG), calculated mass: 4144.7, 
MALDI found: 4143.3 (Figure 2.5). 
Figure 2.4 MALDI of Peptide-PNA-Arg-NH2 conjugate. Calculated mass: 3999.5, 
MALDI found: 3999.0 
 
Figure 2.5 MALDI of peptide-PNA-Arg-MiniPEG conjugate, calculated mass: 





Purification and analysis 
Reverse phase-high performance liquid chromatography (RP-HPLC) at 220 nm 
(for peptides) and 260 nm (for peptide-PNA conjugates) used a TFA/acetonitrile 
gradient to detect and purify the crude peptide. Solvent A: 0.1% TFA/H2O and 
solvent B: 0.1% TFA/acetonitrile with a gradient of 0-35% of B in 35 min, at a flow 
rate 1.0 ml/min was used. The column employed was Varian C-18 column 








Quinone methide intermediates (QMs) are good DNA alkylation agents. However, 
their poor selectivity of alkylation limits their use in biological systems and could 
cause severe side-effects. However, the Rokita group developed a general method for 
selective alkylating DNA based on QM (Scheme 3.1).27 DNA-QMP conjugate was 
formed when N-succinimidyl-3-(3-acetoxymethyl-4-tert-
butyldimethylsilyloxyphenyl)propionate (QMP1) was coupled with ssDNA (OD1). 
Generation of a OD1-QM self-adduct was triggered by adding KF. After the 
complementary ssDNA (OD2) was added, QMP1 was delivered to the targeted DNA 
(OD2) via Watson-Crick base pairing between the two complementary OD1 and 
OD2. The formation of self-adduct is reversible and the QM could be transferred to 
OD2 without the existence of toxic KF.  
  Conjugate OD1-QMP1 was formed by coupling QMP1 and DNA oligonucleotide 
(OD1) (Scheme 3.1). In the procedure, OD1 functions as a vehicle to deliver QMP1 
to target DNA. When QMP1 was mixed with OD1, the N-succinimidyl ester was 
attacked by the amine group from OD1 and formed the conjugate OD1-QMP1.  






Scheme 3.1 Selective delivery of QMP by DNA sequence 
If the DNA is replaced by PNA oligomers, applications may extend to cells. PNA 
oligomers are resistance to degradation by nucleases and proteases, bind with high 
sequence specificity to complementary DNA, and form PNA/DNA duplex with 
higher stability than DNA/DNA duplex. Conjugating various molecules to PNA 
termini has been studied by several groups.57-59 Appella’s group showed that by 
conjugating biotin to a PNA oligomer, fast and simple detection of certain DNA can 
be accomplished without the use of PCR in regular detection.56 Target DNA can be 
detected at a10 zmol (zmol = 10-21 mol) limit. Nielsen also published that conjugation 
of PNAs to a simple lipophilic ligand, such as an adamantyl group, can dramatically 
increase cellular uptake properties compared to PNA itself.57  
  Synthesize the QMP1-peptide-PNA conjugates under a variety of conditions are 
described below. 
 
3.2 Results and Discussion 




  The synthesis of QMP1 was slightly revised from a literature protocol (Scheme 
3.2).27  
 
Scheme 3.2 Synthesis of N-succinimidyl-3-(3-acetoxymethyl-4-tert-
butyldimethylsilyloxyphenyl) propionate 
Previously, after treating 3.1 with NaOH and HCHO, crude products were directly 
added to the DMF solution of TBDMSCl and imidazole. Product 3.3 was purified by 
flash column chromatography in literature.27 Practice showed that the polarity of 3.3 
and 3-[4’-tert-butyldimethylsilyloxy-3’,5’-bis(tert butyldimethylsilyloxymethyl)] 
propionic acid is similar. The separation by flash column chromatography failed. 3.2 
was then dissolved in 10 ml water, the pKa of the aqueous of solution was adjusted to 
pH 2 - 3 by addition of 1M HCl. Because the pH of 3-[3-hydroxymethyl-4-




corresponding acid. 50 ml ethyl ether was used to extract the acid from water. And 
then the corresponding acid was purified by chromatotron (hexane/ethyl acetate = 
2/1). This method avoids the difficulty of separating compounds 3.3 and 3-[4’-tert-
butyldimethylsilyloxy-3’,5’-bis(tert butyldimethylsilyloxymethyl)] propionic acid. 
The yield is 21.2%. 
3.2.2 Conditions for coupling between a QMP1 analog and peptides  
In order to evaluate the conditions for coupling between QMP1 and peptide-PNA 
conjugate, N-succinimidyl-3-(3-bromophenyl)propionate (Br-QMP) and peptide 
(RLRRASLG) S4 were synthesized and coupled in various conditions (Scheme 3.3). 
Br-QMP was used because a) it is easily made from commercially available 3-(3-
bromophenyl) propionate acid and N-hydroxyl succimide; b) the bromide at the 
aromatic ring will generate double peak in mass spectrometer due to the isotope 
distribution of bromide in nature. This signature of bromine-containing conjugate 
makes it easy to judge whether the coupling happens. 
 
Scheme 3.3 Coupling between Br-QMP and peptide S4 
  First attempt to couple BrQMP with peptide S4 was taken under a basic condition. 
Different amount () of DIPEA or triethyl amine (TEA) were mixed with Br-QMP 
and S4, the coupling did not happen (monitored by RP-HPLC). The failure of DIPEA 




amine group from the 5 terminus of peptide-PNA conjugate. Various solvents for the 
reaction such as water, acetonitrile and DMF did not facilitate the coupling. 
Then 3-(N-morpholino)propanesulfonic acid (MOPS) and acetonitrile/DMF system 
was tried. 100 µl peptides (5 mM) dissolved in MOPS (250 mM, pH= 7.5) was mixed 
with 100 µl Br-QMP (7.5 mM) in acetonitrile/DMF (v/v = 2/1) and incubated for 8 
hours at room temperature. RP-HPLC showed that coupling happened (Figure 3.1). 
In the MOPS and acetonitrile/DMF system, several reasons are supposed to 
contribute to the success of coupling: 1) DMF may decrease the aggregation of 
peptide; 2) basic condition rendered by MOPS buffer may help the existence of free 
amine group and then facilitate the coupling. 
Once the condition for coupling between peptides and Br-QMP was determined, 





Figure 3.1 Formation of BrQMP-peptide conjugate, 25.8 min eluent is the conjugate 
3.2.3 Conditions for coupling between Br-QMP, QMP1 and peptide-PNA 
   The same condition in 3.2.2 was used in coupling Br-QMP with peptide-PNA 
conjugate (S1) (Scheme 3.4). 
 
Scheme 3.4 Try to couple Br-QMP with peptide-PNA conjugate S1 
100 µl S1 (5mM) dissolved in Mops (250 mM, pH = 7.5) was mixed with 100 µl 
Br-QMP (7.5 mM) in acetonitrile/DMF (v/v = 2/1). After 24 hours, no reaction 
happened at either room temperature or 37℃ (The RP-HPLC showed no change). 
 The failure of coupling may be that the peptide-PNA chain folds by itself and the 
amine group at the 5’ position is hindered by the PNA chain. Several groups showed 
that Mini-PEG may elongate the peptide chain and keep its amine group far away 
from the PNA backbone.56, 57 S2 was synthesized and coupled with Br-QMP 
following the conditions in 3.2.1 (Scheme 3.5). 
100 µl S2 (1.0 mM) dissolved in MOPS (250mM, pH= 7.5) was mixed with 100 µl 
Br-QMP (3.5 mM) in acetonitrile/DMF (v/v = 2/1). HPLC showed that coupling 




peak is consistent with the coupling product S2-Br-QMP. Calculated mass = 4354.7, 
MALDI found mass: 4353.9 (Figure 3.2) 
 
Scheme 3.5 Coupling between Br-QMP and conjugate S2 
 
Figure 3.2 MALDI of S2-BrQMP (Br-QMP-MiniPEG-R-GTTAGGGTTAG-
LRRASLG), Calculated mass: 4354.7, MALDI found: 4353.9 
Then the same condition was applied to couple final QMP1 with S2. 100 µl S2 
(1.0 mM) dissolved in MOPS (250mM, pH= 7.5) was mixed with 100 µl QMP1 (3.5 
mM) in acetonitrile/DMF (v/v = 2/1) and incubated at room temperature.10 hours 




were collected and examined by MALDI. The calculated mass is 4478.9, MALDI 
found mass is 4477.6 (Figure 3.4). 
 
Figure 3.3 RP-HPLC of peptide-PNA-Arg-PEG-QMP conjugate, 32.5 minute eluent 
was collected and tested by MALDI 
 
Figure 3.4 MALDI of peptide-PNA-Arg-PEG-QMP conjugate, Calculated mass: 




3.2.4 Formation of self-adduct 
3.5 mM QMP1 in MOPS (250 mM, pH = 7.5) was added to 1.0 mM S2 in 
acetonitrile/DMF (v/v = 2/1) at room temperature. The resulting solution was purified 
by RP-HPLC after 24 hours. White solid was collect after lyophilization. The 
formation of self-adduct was accomplished using the protocol from previous paper.27 
200 µl KF (1.0 M) was added into 100µl 2-(N-morpholino)ethanesulfonic acid (MES) 
(20 mM, pH 7.0) that contains S2-QMP1 conjugate (Ca. 20 µM) at room temperature. 
The resulting solution was incubated at room temperature for 8 hours. Self-adduct of 
S2-QMP1 was purified by RP-HPLC. The mass is confirmed by MALDI (Figure 
3.5). Calculated mass is 4305.8, MALDI found mass is 4304.7. 
 





Figure 3.6 MALDI of peptide-PNA-Arg-PEG-QM self-adduct, calculated mass: 
4305.8, MALDI found: 4304.7 
3.2.5 Conclusion: 
Succinimidyl activated QMP was coupled with peptides in Mops-acetonitrile-DMF 
system. The tert-butyloxycarbonyl-8-amino-3,6-dioxaoctanoic acid is essential in 
coupling QMP with peptide-PNA conjugates. RP-HPLC was successfully used to 
monitor the reaction and purify product. In the presence of KF, the S2-QMP1 
conjugate can be converted to its corresponding self-adduct. The self-adduct may 
alkylate complementary DNA sequence later. 
 
3.3 Experimental 
Synthesis of N-hydroxysuccinimidyl-3-(3-bromophenyl)propionate (Br-QMP) 
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) (422 mg, 220 mmol) was 
added to a 50 ml round bottom flask containing 3-(3-bromophenyl)propionate acid 
(458 mg, 200 mmol) and N-hydroxysuccimide (253 mg, 220 mmol) in 12 ml DMF at 




diluted with brine, and extracted with 30 ml ether 3 times. The organic phase were 
combined and washed with brine, dried over MgSO4, and concentrated under reduced 
pressure. The white precipitate appeared at the bottom of the flask. Ethyl ether (5 ml) 
was added to the flask to wash the white solid and the solid was collected by filter the 
solution. The solid was washed by additional 10 ml ether and dried under vacuum to 
yield Br-QMP as a white solid 380 mg. Yield: 58.5%       
1H NMR (CDCl3) δ 7.40 (d, J= 8.4, 2H), 7.08 (d, J= 8.4, 2H), 2.98 (t, J = 7.6, 2H),  
2.86 (m, 2H), 2.82 (s, 4H). 
3-[3-Hydroxymethyl-4-hydroxyphenyl]propionic acid (3.2) 
Ca. 5 ml 10% NaOH aqueous solution was added to 3-(4-hydroxyphenyl) 
propionic acid (2.0 g, 12 mmol), and the pH was adjusted to 8 by NaOH solution. 
Formaldehyde (37%, 5 mL) was added to the resulting solution and stirred at 50° C 
for 17 hours. The resulting yellow solution was poured into 100 ml acetone. The 
orange oil was collected from the bottom of the flask.  The oil was then mixed with 5 
ml methanol and poured into 150 ml acetone to form a white precipitate. The solid 
was collected by filtration. 
The solid was then dissolved in 10 ml water and 1 M HCl was added to adjust the 
pH to 3. The aqueous solution was extracted with 50 ml ether 3 times. After the 
removal of ether by rotoevaporator, the remaining liquid was purified by 
chromatotron (hexane : ethyl acetate = 2 : 1 and 0.5% HOAc) and yielded 3.2 as a 
faint yellow solid (500 mg, 21.2%). 
1H NMR (D2O) δ 7.04 (s, 1H), 6.96 (s, H), 6.72 (s, H), 4.48 (s, 2H), 2.72 (t, J=8, 2H), 




The 1H NMR is consistent with the literature27  
3-[3-tert-Butyldimethylsilyloxymethyl-4-tert-butyldimethylsilyloxyphenyl] 
propionic acid (3.3) 60 
Imidazole (1.02 g, 15 mmol) was added to a solution of tert-butyldimethylsilyl 
chloride (TBDMSCl, 1.50g, 10 mmol) and 3.2 (500 mg, 2.55 mmol) in 12 ml of DMF. 
The mixture was stirred at room temperature for 15 hours, diluted with brine (100 
mL), and extracted with 200 mL ether for 3 times. The organic phases were combined, 
dried over MgSO4, and concentrated under reduced pressure. The product was 
redissolved in 10 ml MeOH and 1.50 g of potassium carbonate was added to the 
methanol solution. The solution was stirred for 3 h and adjusted with 0.2 M HCl to 
pH = 3. The mixture was then diluted with water and extracted with 100 ml ether for 
3 times. The organic phases were combined, washed with brine, dried over MgSO4, 
and concentrated under reduced pressure. The residue was purified by silica gel 
chromatotron (hexane: ethyl acetate= 19:1) to yield 3.3 as a colorless oil (400.5 mg, 
36.9%).  
1H NMR (CDCl3) δ 7.26 (s, 1H), 6.93 (d, J= 8.0, 1H), 6.65 (d, J= 8.0, 1H), 4.17 (s, 
2H), 2.87 (t, J= 8.0, 2H), 2.63 (t, J= 8.0, 2H), 0.98 (s, 9H), 0.18 (s, 6H). 
 The 1H NMR is consistent with the literature27 
3-[3-Acetoxymethyl-4-tert-butyldimethylsilyloxyphenyl] propionic acid (3.4)60 
Solid ferric chloride (10 mg, 0.62 mmol) was added to a solution of 3.3 (200.0 mg, 
0.83 mmol) in acetic anhydride (3 mL) at 0 °C. The reaction mixture was stirred for 
30 minutes and then diluted with 150 mL ether three times. All the organic phase was 




NaHCO3, dried with MgSO4, and concentrated under reduced pressure. The residue 
was subjected to silica gel flash chromatography (hexane: ethyl acetate= 10:1) and 
yielded 3.4 as a colorless liquid (44 mg, 27%). 
1H NMR (CDCl3) δ 7.13 (s, 1H), 7.03 (d, J= 8.0, 1H), 6.74 (d, J= 8.0, 1H), 5.06 (s, 
2H), 2.87 (t, J= 8.0, 2H), 2.63 (t, J= 8.0, 2H), 0.97 (s, 9H), 0.21 (s, 6H). 
The 1H NMR is consistent with the literature27 
N-Succinimidyl-3-(3-acetoxymethyl-4-tert-butyldimethylsilyloxyphenyl) 
propionate (QMP1)27 
N-Hydroxysuccinimide (46 mg, 0.42 mmol) was added to a DMF solution (5.0 mL) 
of 3.4 (40 mg, 0.11mmol). This mixture was cooled to 0 °C and combined with EDCI 
(80 mg, 0.42 mmol). The resulting yellow solution was then stirred for 20 hours from 
4 °C to room temperature, diluted with brine, and extracted with 30 mL ether for 3 
times. The organic phase was combined and washed with brine, dried over MgSO4, 
and concentrated under reduced pressure. The resulting residue was subjected to silica 
gel flash chromatography (hexane: ethyl acetate, 3:1) to yield QMP1 as a white solid 
(24 mg, 47.0%). 
1H NMR (CDCl3) δ 7.14 (s, 1H), 7.05 (d, J= 8.0, 1H), 6.75 (d, J= 8.0, 1H), 5.07 (s, 
2H), 2.97 (t, J= 8.0, 2H), 2.88 (t, J= 8.0, 2H), 2.82 (s, 4H), 2.08 (s, 3H), 0.97 (s, 9H), 
0.21 (s, 6H)  
1H NMR is consistent with the literature27 
Coupling between QMP1 and S2 (NH2-Mini PEG-Arg-PNA-peptide) 
100 µl QMP1 (3.5 mM) in CH3CN/DMF (v/v = 2/1) was mixed with the 




mM, pH 7.5) and incubated for 24 hours at room temperature to generate S2-QMP1 
conjugate. The conjugates were purified by C18 RP-HPLC and monitored at 260 nm. 
The eluents were 0.1% TFA in water and 0.1% TFA in acetonitrile. The gradient was 
10 - 55% in 30 minutes. The 31 - 35 minute eluents were collected and lyophilized. 
The product was confirmed by MALDI-TOF.  
MALDI-TOF (m/z) calculated for the conjugate of S2-QMP1 was 4478.9, and 
MALDI-TOF (m/z) found was 4477.6. 
 Self-Adduct of the S4-QMP1 conjugate  
 200 µl KF (1.0 M) was added to MES (25 mM, pH 7.0) buffer that contains S2-
QMP1 conjugate (20 µM) at room temperature. Self-adduct of S2-QMP1 was 
generated after 8 hours. The conjugates were purified by C18 RP-HPLC at 260 nm. 
The eluents were 0.1% TFA in water and 0.1% TFA in acetonitrile. The gradient was 
10 - 55% in 30 minutes. The 22 - 26 minute eluents were collected and lyophilized. 
The successful generation of self-adduct was confirmed by MALDI-TOF. 
MALDI-TOF (m/z) calculated for the S2-QM self-adduct was 4305.8, and 




Chapter 4 Conclusion 
 
  Quinone methides (QMs) can alkylate DNA and thus have a potential to act as anti-
cancer drugs. In order to improve the target specificity of QM, peptide nucleic acids 
(PNAs) were studied as a delivery agent. PNA oligomers are resistant to degradation 
by nucleases and proteases, bind with high sequence specificity to complementary 
DNA, and form PNA/DNA duplex with higher stability than DNA/DNA duplex. It is 
important to study the synthesis of PNAs and the ability of PNAs as QM delivering 
agents.  
  This thesis focused on the practical synthesis of various peptide-PNA conjugates by 
solid phase peptide synthesis (SPPS). From the synthesis of a 7mer peptide, coupling 
the peptides with a quinone methide precursor (QMP) could be optimized by reacting 
under different kinds of conditions such as reaction concentration, reaction time and 
optimal cleavage conditions. Because PNA monomers are more difficult to dissolve 
in DMF than amino acids, they were normally mixed with DMF and vortexed for 
several minutes to help the dissolvation. PNA monomers also stick to the surface of 
glassware, and thus plastic tubes were used to hold all the PNA solution. 
  C18 Reverse-Phase HPLC (RP-HPLC) also showed the ability to purify both 
peptides and peptide-PNA conjugates at room temperature. The gradient of 
acetonitrile was from 2% to 35% in 30 minutes. Peptide-PNA and peptide-PNA-QMP 
conjugates were eluented out during 20% to 35% acetonitrile. 
  Since the peptide-PNA-QMP conjugate is a key compound in selective delivery of 




amino-3,6-dioxaoctanoic acid (mini-PEG) shows an essential linker in coupling QMP 
with PNA conjugates. Experiments also showed that peptide-PNA conjugated 
dissolved in MOPS buffer (pH = 7.5) and QMP in acetonitrile/DMF = 2/1 guaranteed 
the desired product. MES buffer works for generation of PNA-QM self-adduct by 
adding KF aqueous solution. 
   






























Instructions for the following tables: The sheets can be printed and followed in 
reactions. These sheets mark each step of the sequence--giving the reagents used and 
the times required. Working down a column, each block can be checked off as that 
particular step is completed. When a column is finished, goes to the top of next 
column. 
Appendix 2 Procedures for peptide synthesis  
resin 100 mg (0.7 mmol/g, 70 µmol) was swelled in DMF for three hours 
3-GlyLeuSerAlaArgArgLeu-PNA-Arg-QMP 
AA monomers G Capping L S A R R L 
95% TFA/ m-cresol (2 × 4 
min) 
× ×       
DCM wash (3 × 0.5 min) × ×       
Kaiser test  ×       
DMF wash (1 × 1 min)  ×       
DCM wash (2 × 0.5 min)  ×       
Coupling (20 min)  Capping        
DMF wash (2 × 1 min)         
DCM wash (2 × 1 min)         
Kaiser test         







Appendix 3 Procedures for PNA synthesis  
Resin-kemptide 60 mg (0.7 mmol/g, 42 µmol) was swelled in DMF for three hours 
3-GlyLeuSerAlaArgArgLeu-GATTGGGATTG-Arg-miniPEG-QMP 
PNA monomers G Capping A T T G G G G G A T T G
95% TFA/ m-cresol (2 × 4 
min) 
 ×      ×  ×     
DCM wash (2 × 0.5 min)  ×      ×  ×     
NMP wash (1 × 0.5 min)  ×      ×  ×     
DCM wash (2 × 0.5 min)  ×      ×  ×     
Kaiser test  ×        ×     
DMF wash (1 × 1 min)  ×      ×       
DCM wash (2 × 0.5 min)  ×      ×  ×     
Coupling (20 min)  Capping             
DMF wash (2 × 1 min)               
DCM wash (2 × 1 min)               
Kaiser test ×              










Appendix 7 Amount of amino acids used in SPPS  
resin 100 mg (0.7 mmol/g, 70 µmol) 
 resin G L S A R R L 
M.W. (g/mol)  175 249 295 182 465 465 249 
Eq. to resin  5 5 4 5 4 4 5 
µmol 70 350 350 280 350 280 280 350 
mg 100 61.2 87.2 82.6 63.7 130.2 130.2 87.2 
HBTU (mg)  170.6 170.6 136.4 170.6 136.4 136.4 170.6
DIEA (ul)  57.8 57.8 46.2 57.8 46.2 46.2 57.8 
DMF (ml)  2.5 2.5 2.0 2.5 2.0 2.0 2.5 
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